Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
ACXP Stock Forecast 2026-2027
$1.55
Current Price
$7.20M
Market Cap
Buy 3
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to ACXP Price Targets
+1,900.0%
To High Target of $31.00
+545.2%
To Median Target of $10.00
+545.2%
To Low Target of $10.00
ACXP Price Momentum
+3.3%
1 Week Change
+0.6%
1 Month Change
-82.8%
1 Year Change
-37.8%
Year-to-Date Change
-84.4%
From 52W High of $9.96
+16.9%
From 52W Low of $1.33
📊 TOP ANALYST CALLS
Did ACXP Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Acurx is one of their latest high-conviction picks.
Latest ACXP Stock Price Targets & Analyst Predictions
Based on our analysis of 3 Wall Street analysts, ACXP has a bullish consensus with a median price target of $10.00 (ranging from $10.00 to $31.00). The overall analyst rating is Strong Buy (9.3/10). Currently trading at $1.55, the median forecast implies a 545.2% upside. This outlook is supported by 3 Buy, 0 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Matthew Keller at HC Wainwright & Co., projecting a 1,900.0% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
ACXP Analyst Ratings
3
Buy
0
Hold
0
Sell
ACXP Price Target Range
Low
$10.00
Average
$10.00
High
$31.00
Current: $1.55
Latest ACXP Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for ACXP.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Sep 30, 2025 | HC Wainwright & Co. | Matthew Keller | Buy | Reiterates | $31.00 |
| Aug 12, 2025 | HC Wainwright & Co. | Buy | Maintains | $N/A | |
| May 15, 2025 | HC Wainwright & Co. | Matthew Kelsey | Buy | Assumes | $8.00 |
| Mar 19, 2025 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Jan 13, 2025 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Jan 10, 2025 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Dec 10, 2024 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Nov 14, 2024 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Aug 12, 2024 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| May 16, 2024 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Mar 19, 2024 | HC Wainwright & Co. | Buy | Maintains | $N/A | |
| Feb 28, 2024 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Dec 15, 2023 | HC Wainwright & Co. | Buy | Maintains | $N/A | |
| Nov 15, 2023 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Sep 13, 2023 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Aug 15, 2023 | HC Wainwright & Co. | Buy | Maintains | $N/A | |
| May 15, 2023 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Apr 11, 2023 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Mar 17, 2023 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Jan 10, 2023 | Alliance Global Partners | Buy | Initiates | $N/A |
Acurx Pharmaceuticals, Inc. (ACXP) Competitors
The following stocks are similar to Acurx based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Acurx Pharmaceuticals, Inc. (ACXP) Financial Data
Acurx Pharmaceuticals, Inc. has a market capitalization of $7.20M with a P/E ratio of -0.3x. The company generates $0 in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of 0.0% and return on equity of -160.8%.
Valuation Metrics
Market Cap
$7.20M
Enterprise Value
$-2,163,545
P/E Ratio
-0.3x
PEG Ratio
0.0x
Price/Sales
N/A
Growth & Margins
Revenue Growth (YoY)
N/A
Gross Margin
N/A
Operating Margin
0.0%
Net Margin
0.0%
EPS Growth
N/A
Financial Health
Cash/Price Ratio
+138.9%
Current Ratio
3.8x
Debt/Equity
0.0x
ROE
-160.8%
ROA
-66.5%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Acurx Pharmaceuticals, Inc. (ACXP) Business Model
About Acurx Pharmaceuticals, Inc.
What They Do
Develops innovative antibiotics for bacterial infections.
Business Model
The company operates as a clinical-stage biopharmaceutical firm focusing on the development of antibiotics targeting Gram-positive bacteria. It generates revenue through the advancement of its drug candidates, particularly by attracting partnerships, grants, and potential future product sales once its drugs receive regulatory approval.
Additional Information
Acurx Pharmaceuticals emphasizes combating antibiotic resistance with its unique DNA polymerase IIIC inhibitors. Its lead candidate, ibezapolstat, shows high efficacy against Clostridioides difficile infections, and the company has received important regulatory designations that may accelerate its path to market. Founded in 2017 and based in New York, it is strategically positioned within a critical area of healthcare.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
4
CEO
Mr. David P. Luci CPA, Esq., J.D.
Country
United States
IPO Year
2021
Website
www.acurxpharma.comAcurx Pharmaceuticals, Inc. (ACXP) Latest News & Analysis
Latest News
Quick Summary
Acurx is initiating a Phase 3 trial for ibezapolstat (IBZ) in patients with recurrent CDI, showing potential to shift treatment paradigms. The drug has gained FDA Fast-Track and EMA SME designations.
Why It Matters
The potential success of ibezapolstat (IBZ) in treating recurrent CDI could reshape treatment protocols, impacting Acurx's market position and stock value amid positive regulatory feedback.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
Acurx Pharmaceuticals (NASDAQ: ACXP) will discuss its Q2 2026 financial results on August 14, 2026, at 8:00 am ET, ahead of U.S. market opening.
Why It Matters
Acurx Pharmaceuticals' upcoming financial results may reveal insights into its performance and progress in antibiotic development, influencing investor sentiment and stock valuation.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
Acurx Pharmaceuticals is developing a new class of antibiotics targeting Gram-positive bacteria, with promising results for their drug ibezapolstat. It has FDA QIDP and Fast-Track Designations.
Why It Matters
Acurx's collaboration with LUMC on ibezapolstat could lead to innovative antimicrobials, addressing critical market needs and potentially boosting revenue and stock value for ACXP.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
Acurx Pharmaceuticals (ACXP) has been upgraded to a Zacks Rank #2 (Buy), indicating increased optimism about its earnings prospects.
Why It Matters
Acurx Pharmaceuticals' upgrade to Zacks Rank #2 indicates strong earnings potential, likely boosting investor confidence and driving stock price upward.
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
Acurx Pharmaceuticals, Inc. (ACXP) held its Q1 2026 earnings call, discussing financial performance and future strategies. Further details are available in the transcript.
Why It Matters
Acurx Pharmaceuticals' Q1 2026 earnings call provides insights into financial performance, future projections, and strategic initiatives, influencing stock valuation and investment decisions.
Source: Seeking Alpha
Market Sentiment:
Neutral
Acurx Pharmaceuticals, Inc. Reports First Quarter 2026 results and Provides Business Update
2 months ago
Quick Summary
Acurx Pharmaceuticals (NASDAQ: ACXP) reported its Q1 2026 financial and operational results, focusing on developing new antibiotics for challenging bacterial infections.
Why It Matters
Acurx's financial and operational results may indicate the company's progress and potential market performance, influencing investor confidence and stock valuation in the biopharmaceutical sector.
Source: PRNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About ACXP Stock
What is Acurx Pharmaceuticals, Inc.'s (ACXP) stock forecast for 2027?
Based on our analysis of 3 Wall Street analysts, Acurx Pharmaceuticals, Inc. (ACXP) has a median price target of $10.00. The highest price target is $31.00 and the lowest is $10.00.
Is ACXP stock a good investment in 2027?
According to current analyst ratings, ACXP has 3 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $1.55. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for ACXP stock?
Wall Street analysts predict ACXP stock could reach $10.00 in the next 12 months. This represents a 545.2% increase from the current price of $1.55. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Acurx Pharmaceuticals, Inc.'s business model?
The company operates as a clinical-stage biopharmaceutical firm focusing on the development of antibiotics targeting Gram-positive bacteria. It generates revenue through the advancement of its drug candidates, particularly by attracting partnerships, grants, and potential future product sales once its drugs receive regulatory approval.
What is the highest forecasted price for ACXP Acurx Pharmaceuticals, Inc.?
The highest price target for ACXP is $31.00 from Matthew Keller at HC Wainwright & Co., which represents a 1,900.0% increase from the current price of $1.55.
What is the lowest forecasted price for ACXP Acurx Pharmaceuticals, Inc.?
The lowest price target for ACXP is $10.00 from at , which represents a 545.2% increase from the current price of $1.55.
What is the overall ACXP consensus from analysts for Acurx Pharmaceuticals, Inc.?
The overall analyst consensus for ACXP is bullish. Out of 3 Wall Street analysts, 3 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $10.00.
How accurate are ACXP stock price projections?
Stock price projections, including those for Acurx Pharmaceuticals, Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: July 18, 2026 2:01 AM UTC